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Background: Antenatal and postnatal treatment with dexamethasone (DEX) may negatively affect the
neuropsychological development in children. Maternal anti-Ro/Sjo¨gren’s syndrome A (SSA) antibodies
may also be associated with learning disabilities in offspring.
Objective: To assess neuropsychological development in babies exposed to very high dosages of DEX in
utero, whose mothers were anti-Ro/SSA positive.
Methods: 13 children with congenital complete heart block (CHB) (11 exposed and 2 not exposed to DEX)
and 3 healthy siblings, all of anti-Ro/SSA-positive women, were evaluated. 11 preschool-aged children (5
boys) were assessed using Griffiths Mental Development Scales. 5 school-aged children (2 boys) were
examined using Wechsler Intelligence Scale for Children—Revised to check IQ and reading tests to
explore the existence of learning disabilities or dyslexia. None of the children had had major neonatal
complications, although those with CHB had to be paced at different intervals from birth.
Results: The children had been exposed in utero to a mean total dose of 186.6 mg DEX. IQ levels were
always normal (mean IQ 105.1, standard deviation (SD) 9.5). Only one child had a learning disability, of
borderline clinical significance, but this child had never been exposed to DEX.
Conclusion: No negative effects were found on the neuropsychological development in this cohort of
children, even if they had been exposed to maternal anti-Ro/SSA antibodies and to very high dosages of
DEX (much higher than those used to improve fetal lung maturity). These findings might be of interest in
view of the large number of infants exposed in the past to repeated antenatal courses of steroids.
F
indings in animals1–3 and humans4–7 suggest that
antenatal and postnatal treatment with dexamethasone
(DEX) may negatively affect neuropsychological devel-
opment in infants. In addition, the presence of maternal anti-
Ro/Sjo¨gren’s syndrome A (SSA) antibodies may be associated
with learning disabilities in offspring.8
Small trials support the benefit of fluorinated steroids in
the treatment of congenital heart block (CHB),9 10 which
occurs in utero in approximately 1–2% of anti-Ro/SSA-
positive mothers,11 12 but the question remains controversial.
Usually, DEX 4 mg daily is given to prevent progression of
incomplete heart block to the fibrotic irreversible state of
complete CHB, or to treat myocarditis or fetal hydrops.13
These fetuses are exposed to much higher dosages of DEX or
bethametasone than the single course of 24 mg usually given
to pregnant women at risk of preterm delivery to reduce the
risk of death, respiratory distress syndrome and cerebral
haemorrhage in their premature infants.14
Our study assessed neuropsychological development in a
small cohort of babies exposed to very high dosages of DEX in
utero, whose mothers were also anti-Ro/SSA positive. CHB is
a rare condition, but our findings may be clinically relevant in
view of the large number of newborns who were exposed in
the past to repeated courses of antenatal steroids to induce
fetal lung maturity.
PATIENTS AND METHODS
Patients
From 1992 to 2004, we observed 17 babies born with
complete CHB, most of whom had been treated in utero
with high-dose DEX. Three died soon after birth from
intractable heart failure; another, born in August 2001,
developed severe dilated cardiomyopathy in 2002, and his
parents did not consent to his enrolment in this study. We
investigated the remaining 13 babies. There was one twin
pregnancy and one of triplets; only one of the twins and one
of the triplets had complete CHB, but we studied the other
three as well, as they had been exposed to the same dose of
DEX in utero. Thus a total of 16 children were studied. Table 1
summarises their clinical features. All were delivered by
caesarean section.
Mean weight (standard deviation (SD)) was 2033 (505) g
and mean (SD) gestational age was 35.1 (2) weeks at birth.
In all, 11 infants (68.7%) were born preterm (,37 weeks of
gestational age) and 6 (37.5%) were small for gestational age
(,10th centile for birth weight). Three infants small for
gestational age also had a small cranial circumference for
their gestational age; the others were all normal. They all
were in good clinical condition, as is usual in surviving
babies with complete CHB,15 with an uneventful clinical
course. No complications were seen in terms of the common
diseases or pathologies, sometimes very severe, which may
affect the preterm newborn and consequently, later in life,
exert a negative influence on neuropsychological develop-
ment. All were paced, at different ages (table 1). None
developed clinical features of autoimmune conditions or of
Abbreviations: CHB, complete heart block; DEX, dexamethasone; SSA,
Sjo¨gren’s syndrome A; WISC—R, Wechsler Intelligence Scale for
Children—Revised
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immunodeficiency. The babies were exposed in utero to a
mean total dose of 186.6 mg DEX (range 0–551; table 1): 14
babies had been treated in utero with high-dose DEX,
whereas two (patients 8 and 15) were exposed only to a
single course of bethamethasone (24 mg) but not to DEX, as
they came to our attention only for delivery. However, we
included them as internal controls—that is, babies with CHB
exposed to anti-Ro/SSA antibodies but not to DEX. All of the
13 mothers were anti-Ro/SSA positive; 7 had an undiffer-
entiated connective tissue disease and 6 had primary
Sjo¨gren’s syndrome. Antibodies to Ro/SSA were determined
by counterimmunoelectrophoresis and immunoblotting as
previously described.16
Methods
At the time of this study, the children’s mean age was 5
(range 2–12) years. The Niguarda Hospital internal review
board approved the protocol. With the parents’ written
informed consent, 16 children were included in this study
in 2004. Eleven were of preschool age (mean age 30.1, range
14–65 months) and five of school age (7–11 years).
To evaluate the development of children aged ,6 years, we
used the Griffiths Mental Development Scales,17 which
evaluate mental age in relation with chronological age and
a general developmental quotient (IQ), which is the average
of six different items (locomotor, personal–social, hearing
and speech, hand and eye coordination, performance and
practical reasoning scales). For children aged .6 years, we
used the Wechsler Intelligence Scale for Children—Revised
(WISC-R),18 which comprises verbal and performance tests,
for assessing a total IQ, a verbal IQ and a performance IQ. To
directly evaluate any learning disabilities, children aged
.7 years were also tested for reading skills, using test
numbers 4 and 5 of the Sartori test19 and the MT test20;
these measure the speed and correctness of reading. In
addition, a thorough neuropsychiatric assessment of the
children and their behaviour was carried out during the tests.
A diagnosis of learning disability can be made when the
results are lower than 2 SD from the mean for the general
population of the same age and IQ.
RESULTS
Tables 2 and 3 summarise the results of preschool-aged and
school-aged children, respectively. The mean IQ was 105.1
(range 91–121, median 104, SD 9.5). Mental retardation is
defined by an IQ of ,70, so all 16 children were of normal
intelligence. We found no significant differences between
mental age and chronological age for the 11 preschool infants
and the developmental quotient was always within the
normal range (p.0.01).
All five school children had a total IQ in the normal range.
The child with congenital sensorineural deafness (patient
Table 1 Newborn features, date of birth and age of permanent pacing
Patient Sex
Year
of
birth
GA
CHB
Lower
fetal
HR
GA at
delivery
HR at
birth
Apgar
score
Fetal
heart
failure
DEX
exposure
(mg)
Birth
weight
(g) Centile
Birth HC
(cm) Centile
Age of
permanent
pacing
1 M 2002 24 55 35 40 5–8 No 242 2080 25 32 50 7 days
2 M 2002 24 45 34 45 5–8 Pericardial
effusion
196 1640 3–10 NR NR 5 weeks
3 F 2002 NA NA 34 110 9–9 No 196 1630 3–10 NR NR
4 F 2001 24 52 33 50 5–8 Hydrous 160 1870 25 NR NR 6 weeks
5 F 2001 NA NA 33 110 8–9 No 160 1900 25–50 NR NR
6 M 2001 NA NA 33 115 9–9 No 160 1870 50 NR NR
7 F 2001 18 70 35 80 9–9 No 551 2050 10–25 35 97 11 months
8 M 2000 20 50 38 60 8–9 No 0 2900 25 32 3 2 days
9 F 2000 20 62 38 70 8–9 No 240 2900 50 32 10 3 months
10 M 2000 20 55 32 50 9–9 No 84 1300 3–10 25 ,3 2 months
11 F 1998 20 47 33 48 9–9 No 260 1430 3–10 25 ,3 30 days
12 M 1997 23 62 33 50 8–9 No 95 1645 10–25 30 25 3 months
13 F 1996 32 30 36 58 8–9 No 84 2770 50–75 33.5 75 3 days
14 F 1995 26 60 38 52 8–9 No 240 2600 10–25 32 10 8 months
15 F 1992 29 50 37 50 9–9 No 0 2050 3 32.5 25 10 years
16 M 1996 21 64 38 60 8–9 No 318 1900 ,3 33 10–25 3 years
Mean 23.2 54 35.1 54.8 186.6 2033.4
Range 18–32 30–70 32–38 40–80 0–551 1300–2900
CHB, complete heart block; DEX, dexamethasone; F, female; GA CHB, gestational age at detection of CHB; HC, head circumference; HR, heart rate; M, male; NA, not
applicable; NR, not registered.
Patients 3, 5 and 6 did not have CHB.
Table 2 Results of Griffiths test in preschool children
Patient Sex
DEX exposure
(mg)
Chronological age
(months)
Mental age
(months)
Developmental quotient
(nv.70)
1 M 242 14 13 95
2 M 196 20 20 112
3 F 196 20 20 114
4 F 160 29 29 101
5 F 160 29 31 106
6 M 160 29 31 107
7 F 551 34 31 91
8 M 0 42 50 121
9 F 240 45 53 118
10 M 84 48 48 101
11 F 260 65 60 93
DEX, dexamethasone, F, female; M, male.
Patients 3, 5 and 6 did not have complete heart block.
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13), whose father and one sibling had the same congenital
defect, showed a marked discrepancy between verbal IQ and
performance IQ, clearly related to the deafness; however, the
IQ was still normal, thanks to an excellent performance IQ.
Owing to deafness, decoding ability and text understanding
were not tested in this child.
In child 15, a discrepancy was observed between decoding
ability and reading tests, and this will need to be checked
during follow-up. This baby was not exposed to DEX in utero.
As regards maternal side effects related to DEX, the mother
of patient 9 developed transient incapacitating insomnia and
the mother of patient 10 had a recurrence of a transient acute
psychosis; both were concurrently treated with high-dose
salbutamol. As regards the fetuses, it is difficult to relate the
mild prematurity and some cases of oligohydramnios to DEX
or to the global course of the pregnancy complicated by CHB.
DISCUSSION
Liggins21 in 1972 first showed that treating women with
betamethasone almost halved the incidence of respiratory
failure in the offspring. Despite increasing evidence of the
benefit of antenatal corticosteroids over the ensuing two
decades, obstetricians were slow to adopt them. To assess the
effectiveness of this antenatal treatment, the National
Institutes of Health sponsored a Consensus Development
Conference in 1994 on how corticosteroids for fetal matura-
tion affected perinatal outcomes. The consensus panel
concluded that a single course of corticosteroids (betametha-
sone or DEX, 24 mg) given to pregnant women at risk of
preterm delivery, between 24 and 34 weeks of gestational
age, clearly reduced the risk of death, respiratory distress
syndrome and cerebral haemorrhage in their preterm
infants.14 Since then, this practice has became more popular
among doctors, and it is now common practice among
obstetricians to prescribe weekly antenatal steroid courses to
women undelivered after the first dose.22
However, accumulated evidence suggests the potential
harm of repeated courses of steroids for the mother and the
fetus. Findings on animals widely suggest that repeated
antenatal doses of steroids can interfere with the growth and
development of the immature brain1–3 and observations on
humans suggest that antenatal and postnatal DEX may
negatively affect the child’s neuropsychological develop-
ment.4–6 Furthermore, postnatal magnetic resonance indices
of infant brain maturation suggest a potential negative effect
of multiple antenatal steroid doses.23 Recent data suggest that
rates of disabilities and educational difficulties are high in
infants with neonatal chronic lung disease, but with no
marked differences between infants treated and those not
treated with DEX.24 Prematurity itself is associated with mild
brain structural differences that persist at 8 years of age, with
associated lower neurocognitive scores, but perinatal hydro-
cortisone had no long-term effects on either neurostructural
brain development or neurocognitive outcomes.25
These data on animals and humans refer almost exclu-
sively to fluorinated steroids, and doses applied were lower
than those used in our cohort of children.
The possible negative effects seem to be linked more to
DEX than to betamethasone,6 and it has been suggested that
betamethasone should be preferred when available.7 26 A
separate meta-analysis of the data in the Cochrane Review
shows that only betamethasone and not DEX considerably
reduces neonatal mortality.27 In view of this concern, another
National Institutes of Health Consensus Conference in 2000
confirmed the previous statement of the advantages of one
course of antenatal corticosteroids but also made it clear that,
considering their potential hazard, repeated courses should
not be given routinely but reserved for patients in rando-
mised controlled clinical trials.28
Small trials support the benefit of fluorinated steroids in
the treatment of children with CHB of anti-Ro/SSA-positive
mothers,9 10 although the question remains controversial. The
presence of maternal anti-Ro/SSA antibodies as such may be
associated with learning disabilities in offspring.8 In the light
of these findings, babies with CHB who are both treated in
utero with high-dose DEX and exposed to maternal anti-Ro/
SSA antibodies should be at very high risk of neurodevelop-
mental defects.
Recently, 28 questionnaires were evaluated from families
enrolled in the Research Registry for Neonatal Lupus on
neuropsychiatric development in 15 affected children (10
with CHB and 5 with neonatal lupus rash) and 13 unaffected
siblings, all exposed to maternal anti-Ro/SSA antibodies.29 Of
the 10 children with CHB, five were reported by a doctor,
nurse or teacher to have a neuropsychiatric disorder (three
had attention disorders, two had behavioural problems
requiring drugs, one had behavioural and speech problems
and one had depression); also for three children with CHB,
parents reported that they had difficulty concentrating and
paying attention. Of the five children with neonatal lupus
rash, one had depression, one had vision and speech
problems and one parent-reported difficulty concentrating
and paying attention. A similar high frequency of neuropsy-
chiatric disorders was observed in the 13 unaffected anti-Ro/
SSA-exposed children: one had anxiety and speech problems,
two had speech problems, one child was receiving drugs for
an attention problem, and two had parent-reported difficulty
concentrating and paying attention. The possibility of
sampling bias clearly exists, as the authors acknowledge,
and these children were not formally tested using neurop-
sychiatric scales.29
In view of this background, we were worried about our
patients with CHB and decided to test them formally for
neuropsychological development, IQ and learning disabilities.
All of them had normal IQ; only one school girl had a mild
learning disability, expressed by a discrepancy between
decoding ability and reading test, but she was one of the
two babies who was never exposed to DEX in utero. Cranial
circumference values at birth were normal for gestational
Table 3 Results of Wechsler Intelligence Scale for Children—Revised test in school children
Patient Sex Age in 2004
DEX exposure
(mg) IQ (nv.70)
Verbal IQ
(nv.70)
Performance IQ
(nv.70)
Decoding ability
(quick reading) Text understanding
12 M 7 y 95 96 88 105 Age adequate Age adequate
13 F 7 y 11 m 84 100 72 133 Not assessed Not assessed
14 F 8 y 3 m 240 118 118 112 Age adequate Age adequate
15 F 11 y 5 m 0 100 100 101 Age adequate 20.94SD
16 M 7 y 6 m 318 109 120 95 Age adequate Age adequate
DEX, dexamethasone; F, female; m, months; M, male; nv, normal value; WCIS—R, Wechsler Intelligence Scale for Children—Revised; y, years.
Patient 13 has congenital sensorineural deafness.
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age, except in three children who had a small cranial
circumference for their gestational age.
We studied only a small cohort of patients, with a relatively
short follow-up, but they were exposed to very high antenatal
dosages of DEX. The small number means we cannot draw
any firm conclusion about any hypothetical negative effects
on brain development or function. In addition, in children
aged ,5 years, there is considerable individual variability,
making it difficult to assess subtle neurocognitive deficits. As
regards possible attention-deficit hyperactivity disorder and
other behavioural problems that would not be scored on the
IQ testing, the normal responses to test numbers 4 and 5 of
the Sartori test19 and of the MT test,20 and particularly the
observation of the child’s behaviour during the tests, enabled
our neuropsychiatrists to exclude this risk.
Interestingly, in our small sample of children with CHB, we
did not find the bias possibly present in other studies, as
there were no cases of the severe pathologies that often affect
preterm newborns and can influence brain damage, and
hence neurological impairment.24 We did not have the
selection bias that might have been present in the other
similar report.29
On the basis of the data from the literature,6 7 26 27 we are
now using bethametasone in patients with incomplete CHB
or hydropic CHB, like others.30 We were reassured to see that
all our patients with CHB had normal IQ, with no learning
disabilities, despite the exposure to high-dose DEX and to
maternal anti-Ro/SSA antibodies. Although, it is quite
possible that a repeated course of DEX may be detrimental
to the newborn’s neurodevelopment, a child’s final intellec-
tual maturation remains an extremely complex process,
involving the interplay of many biological, social and cultural
factors (fig 1).
In conclusion, we observed no negative effects on the
neurodevelopment in our cohort of children, many of whom
were exposed to very high dosages of DEX (much higher than
those used to improve fetal lung maturity) and to maternal
anti-Ro/SSA antibodies. CHB is a rare condition, but these
reassuring findings might be clinically relevant in view of the
large number of newborns treated in the past with repeated
courses of antenatal fluorinated steroids to induce fetal lung
maturity.
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